File copy
10/041,845

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute Form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	10/041,845
Filing Date	October 18, 2001
First Named Inventor	Fred LEVINE et al.
Art Unit	1636
Examiner Name	To Be Assigned D. LAFFERTY
Attorney Docket Number	023070-110910US

RECEIVED

DEC 27 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
<i>DL</i>	1	US-5,424,286		06-13-1995	Eng	
<i>DL</i>	2	US-5,545,618		08-13-1996	Buckley et al.	
<i>DL</i>	3	US-5,614,492		03-25-1997	Habener	
<i>DL</i>	4	US-5,670,360		09-23-1997	Thorens	
<i>DL</i>	5	US-5,705,483		01-06-1998	Galloway et al.	
<i>DL</i>	6	US-5,723,333		03-03-1998	Levine et al.	
<i>DL</i>	7	US-5,849,989		12-15-1998	Edlund	
<i>DL</i>	8	US-5,858,973		01-12-1999	Habener et al.	
<i>DL</i>	9	US-5,888,816		03-30-1999	Coon et al.	
<i>DL</i>	10	US-5,977,071		11-02-1999	Galloway et al.	
<i>DL</i>	11	US-5,981,488		11-09-1999	Hoffmann	
<i>DL</i>	12	US-6,087,129		07-11-2000	Newgard et al.	

#6

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
<i>DL</i>	13	PCT	WO 97/16536		05-09-1997			<input type="checkbox"/>
<i>DL</i>	14	PCT	WO 00/09666	A2	02-24-2000			<input type="checkbox"/>

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>DL</i>	15	BEATTIE, G.M. et al. "Sustained proliferation of PDX-1 ⁺ cells derived from human islets," <i>Diabetes</i> May 1999, pp. 1013-1019, Vol. 48.	
<i>DL</i>	16	D'AMBRA, R. et al. "Regulation of insulin secretion from β -cell lines derived from transgenic mice insulinomas resembles that of normal β -cells," <i>Endocrinol.</i> 1990, pp. 2815-2822, Vol. 126, No. 6.	
<i>DL</i>	17	DUFAYET DE LA TOUR, D. et al. " β -cell differentiation from a human pancreatic cell line <i>in vitro</i> and <i>in vivo</i> ," <i>Mol. Endocrinol.</i> 2001, pp. 476-483, Vol. 15, No. 3.	


Examiner
Signature*David Lambertson*Date
Considered

9/20/03

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1415395 v1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/041,845
Filing Date	October 18, 2001
First Named Inventor	Fred LEVINE et al.
Art Unit	1636
Examiner Name	To Be Assigned - D. LAUBERTSON
Attorney Docket Number	023070-110910US

RECEIVED

DEC 27 2002

TECH CENTER 1600/2901

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DL	18	HALVORSEN, T.L. et al. "Telomerase activity is sufficient to allow transformed cells to escape from crisis," <i>Mol. & Cell. Biol.</i> March 1999, pp. 1864-1870, Vol. 19, No. 3.	
DL	19	SHARMA, S. et al. "Hormonal regulation of an islet-specific enhancer in the pancreatic homeobox gene <i>STF-1</i> ," <i>Mol. & Cell. Biol.</i> May 1997, pp. 2598-2604, Vol. 17, No. 5.	
DL	20	XU, G. et al. "Exendin-4 stimulates both β -cell replication and neogenesis, resulting in increased β -cell mass and improved glucose tolerance in diabetic rats," <i>Diabetes</i> December 1999, pp. 2270-2276, Vol. 48.	
DL	21	ZHOU, J. et al. "Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon-and insulin-producing cells," <i>Diabetes</i> December 1999, pp. 2358-2366, Vol. 48.	

Examiner
Signature

David Laubertson

Date
Considered

9/20/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1415395 v1